Actively Recruiting
Evaluating the Safety and Effectiveness of OT202 Eye Drops Compared to Placebo for Moderate to Severe Dry Eye in Adults Aged 30 to 75
Led by Ocumension Therapeutics (Suzhou) Co., Ltd · Updated on 2026-10-15
842
Participants Needed
49
Research Sites
17 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a Phase III clinical trial to evaluate the safety and effectiveness of OT202 ophthalmic solution for treating adults aged 30 to 75 years with moderate to severe dry eye. The study is randomized, double-blind, and placebo-controlled, aiming to compare OT202 with a placebo in improving dry eye symptoms. The main measures include changes in corneal staining and eye dryness scores after 56 days of treatment. Participants will be randomly assigned to receive either 1% OT202 eye drops or a placebo, both administered as 1 to 2 drops three times daily in the conjunctival sac. The study includes a screening period, a run-in phase, an 8-week double-blind treatment, and long-term safety follow-up cohorts lasting 10, 28, and 54 weeks. After the double-blind phase, all participants will receive open-label OT202. Pharmacokinetic assessments will be done in a subset of participants. During the study, participants will attend scheduled visits for eye exams, symptom assessments, and safety monitoring. Tests include corneal fluorescein staining, tear film break-up time, Schirmer I test, and various dry eye questionnaires. Researchers will monitor adherence to treatment and evaluate changes from baseline in key eye dryness measures. Follow-up continues for up to 54 weeks to observe long-term safety and effects, with total participation lasting several months depending on cohort assignment.
CONDITIONS
Brief Title
Phase III Study of OT202 in Treating Moderate to Severe Dry Eye
Research Team
W
Wei Chen
J
Jia Qu
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here